Hilltop Leaf, the company behind one of the UK’s first medicinal cannabis cultivation and production facilities, has raised £2m from Traditum Private Equity and private investors.  The funding will enable the company to make its first commercial sales and scale its infrastructure to become one of the largest UK producers of medicinal cannabis products for the specialist prescription market. 

QV Bioelectronics, creators of an innovative surgically implanted Electric Field Therapy (EFT) device for the treatment of brain tumours – has secured £2m in Pre-Series A funding from new and existing leading deep tech investors. The round was led by the Science Angel Syndicate and Fink Family Office with participation from Northern Gritstone, Elbow Beach Capital, and existing investors SOSV and Catapult Ventures.

Oxford Innovation EIS Growth Fund and OION Angels invest 14% of Qkine’s latest £4.3 million fund raise which was co-led by Parkwalk Advisors Ltd and Downing Ventures.

Two leading doctors who developed a new health coaching platform after the untimely death of a colleague have raised over £1m in a funding round led by private equity firm Traditum and backed by angel investors.  The funding will enable physiologist and serial entrepreneur Dr Michael Stein and Oxford University’s Professor Chris Butler to develop their Added Health platform further and roll it out to a wider audience.

Jellagen, an innovative biotech company and leader in biomaterials derived from jellyfish, has closed a successful £8.7m Series A equity investment round.

USA: The Launch Place has announced its $250,000 investment in Revibe Technologies, a North Carolina-based startup developing digital therapy software for wearables to treat attention-deficit/hyperactivity disorder (ADHD) and autism. After bringing its flagship artificial intelligence-driven smartwatch and wristband to the adolescent market, the company is iterating on its success with FokusRx—a nonpharmacologic software-as-a-medical device (SaMD) approach to treating attention and focus deficits.

Healthtech startup, Virtue Health Group Limited (Virtue), has secured £1 million in seed funding in an investment round led by the Midlands Engine Investment Fun (MEIF) managed by Midven, part of the Future Planet Capital Group. The company has secured £500,000 from the MEIF as well as further investments from QVentures and a number of business angels.

Hearing Diagnostics, the Edinburgh-based healthtech company, is eyeing commercialisation in the domestic and US markets following a £1.1m fundraise.

Led by Archangels, the world’s longest continually running angel investment syndicate, the funding will unlock the spatial hearing screening technology’s market potential. Other funders in the raise include Scottish Enterprise through its Scottish Co-Investment Fund.

London-based Period care and sexual health brand Here We Flo has raised £1.7m in an angel funding round, supported by Angel Investment Network, the world’s largest online angel investment platform. 

Here We Flo’s mission is ‘shamelessly natural care for life’s messiest moments’. The brand intends to challenge, shame and disrupt the period, bladder and sexual wellness markets with organic and vegan products. 

Every material is sourced with sustainability in mind and free of any dyes, pesticides, petroleum plastics and other contaminants that may impact health. The product list includes FLO Period Care, glo Sensitive Bladder Care and XO! Sexual Wellness.

University of Birmingham spinout ChromaTwist Ltd has secured £487k of equity investment to develop its new class of fluorescent dyes for the flow cytometry reagent market.

This second round of equity investment, which brought in funds from Directors, existing Angel investors, angelgroups and the University of Birmingham will allow the company to continue product development with industry partners, and enable rapid development of products for market entry as soon as 2023. 

Mid Atlantic Bio Angels Group (MABA) has made an investment in The Shape Sensing Company (TSSC).

A company based at Queen’s University, Belfast which has developed a potentially life-saving new cancer treatment is to invest almost £8m to take its first anti-cancer drug through a first-in-human, Phase 1a clinical trial and perform further scientific development work.